It is currently 29 Sep 2020 22:27

All times are UTC + 5:30 hours [ DST ]




Post new topic Reply to topic  [ 1 post ] 
Author Message
PostPosted: 27 Jul 2020 15:26 
Offline
User avatar

Joined: 24 Mar 2013 02:28
Posts: 751
Encouraging results from phase 1/2 COVID-19 vaccine trials

Lancet July 20, 2020

The results of two early phase COVID-19 vaccine trialsare reported, one from investigators at the Jenner Institute at Oxford University (Oxford, UK), with support from AstraZeneca, and the second from investigators supported by CanSino Biologics in Wuhan, China.

Both groups used an adenoviral vector, and both report the vaccine achieving humoral responses to the SARS-CoV-2 spike glycoprotein receptor binding domain by day 28 as well as T-cell responses. Both report local and systemic mild adverse events such as fever, fatigue, and injection site pain. In neither trial was a severe adverse event reported.

Andrew Pollard and colleagues report their phase 1/2 randomised trial of one injection of chimpanzee adenovirus-vectored COVID-19 vaccine.
Vaccine formulation at one concentration was tested against a comparator quadrivalent conjugate meningococcal vaccine among 1077 healthy adults (50% male, 90·9% white) aged 18–55 years (median 35 years, IQR 28–44), recruited from five centres in the UK and followed up for 28 days.

Local and systemic adverse events such as fatigue, headache, and local tenderness occurred commonly in COVID-19 vaccinees, but were tolerable and mostly ameliorated by paracetamol. No serious adverse events occurred.

Neutralising antibodies were generated in more than 90% of participants across different assays. Responses were sustained up to 56 days of observation. A small non-randomly selected, second-dose boosted subset showed strong neutralising responses, and few mild adverse events. Importantly, T-cell responses were induced in all participants.


Wei Chen and colleagues report results from a phase 2 randomised trial of one injection of non-replicating adenovirus-vectored COVID-19 vaccine.
Vaccine formulation at two concentrations (ie, 1 × 1011 or 5 × 1010 viral particles per mL) were tested against placebo among 508 healthy COVID-19 unexposed adults (50% male) aged 18-83 years (mean 39·7 years) recruited from one centre in Wuhan, China, and followed up for 28 days.

Adverse events such as fever, fatigue, headache, or local site pain occurred by day 28 in 294 (77%) of 382 vaccinees and 61 (48%) of 126 placebo recipients. Male sex was associated with lower occurrence of fever post-vaccination. No serious adverse events occurred.

Seroconversion occurred in more than 96% of participants, and neutralising antibodies were generated in about 85%. More than 90% had T-cell responses. People older than 55 years of age had somewhat lower humoral responses (although still higher than placebo), as did people with previous vector immunity, but these factors did not affect T-cell responses. Immunogenicity did not differ by sex.

These trial reports are hugely anticipated. The results of both studies augur well for phase 3 trials, where the vaccines must be tested on much larger populations of participants to assess their efficacy and safety. Overall, the results of both trials are broadly similar and promising, notwithstanding differences in the vector, in the geographical locations of the populations studied, and the neutralisation assays used.

Without drawing causal inference, the exploration of associations of age and sex with adverse events and immunogenicity reported by Chen and colleagues, and of longevity of response by Pollard and colleagues, are welcomed, given the differential burden of severe outcomes in older adults, and the emerging science around differential sex-specific vaccine effects.

These COVID-19 vaccine trials are small so inferential caution is warranted, but the explorations are laudable. Ethnic diversity in both these trials was very limited.


Top
 Profile Send private message  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC + 5:30 hours [ DST ]


Who is online

Users browsing this forum: No registered users and 3 guests


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Jump to:  
cron